Zoetis Inc. (NYSE:ZTS) Shares Sold by PDS Planning Inc

PDS Planning Inc lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 8.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,088 shares of the company’s stock after selling 203 shares during the quarter. PDS Planning Inc’s holdings in Zoetis were worth $412,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. River Street Advisors LLC boosted its position in Zoetis by 3.4% during the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after purchasing an additional 58 shares during the period. Perigon Wealth Management LLC lifted its holdings in shares of Zoetis by 0.3% during the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock worth $4,654,000 after buying an additional 59 shares during the last quarter. TFC Financial Management Inc. lifted its holdings in shares of Zoetis by 3.3% during the third quarter. TFC Financial Management Inc. now owns 1,918 shares of the company’s stock worth $334,000 after buying an additional 61 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Zoetis by 5.0% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,281 shares of the company’s stock worth $253,000 after buying an additional 61 shares during the last quarter. Finally, Townsend Asset Management Corp NC ADV lifted its holdings in shares of Zoetis by 0.3% during the third quarter. Townsend Asset Management Corp NC ADV now owns 22,585 shares of the company’s stock worth $3,929,000 after buying an additional 66 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock traded up $4.28 during mid-day trading on Tuesday, hitting $149.82. 1,768,375 shares of the company were exchanged, compared to its average volume of 3,033,663. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The business has a fifty day moving average of $174.45 and a 200 day moving average of $179.97. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a market capitalization of $68.52 billion, a PE ratio of 29.35, a price-to-earnings-growth ratio of 2.24 and a beta of 0.85.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The business had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.15 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 5.79 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.15%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Piper Sandler reiterated an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. The Goldman Sachs Group upped their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Barclays cut their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Stifel Nicolaus cut their target price on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $218.00.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 2,209 shares of company stock valued at $371,293. 0.15% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.